Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.
about
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinomaBarrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesisBarrett's oesophagus: from metaplasia to dysplasia and cancerBarrett's oesophagus and adenocarcinomaDNA index determination with Automated Cellular Imaging System (ACIS) in Barrett's esophagus: comparison with CAS 200Circulating Tumor Cells in the Adenocarcinoma of the EsophagusGenetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-AnalysisRecent development of optical coherence tomography for preoperative diagnosis of esophageal malignancies.Early events during neoplastic progression in Barrett's esophagusEpidemiology of Barrett's Esophagus and Esophageal AdenocarcinomaPredictive biomarkers for Barrett's esophagus: so near and yet so farSurgical indications and optimization of patients for resectable esophageal malignanciesMolecular changes in the progression of Barrett's oesophagusAberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinomaTargeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human resultsGlobal DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use.Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagusPhotodynamic therapy in Barrett's esophagus: results of treatment of 17 patients.Endoscopic mucosal resection of Barrett's oesophagus containing dysplasia or intramucosal cancer.Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy.Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective.Low grade dysplasia in Barrett's esophagus: Should we worry?Translation of an STR-based biomarker into a clinically compatible SNP-based platform for loss of heterozygosity.The molecular basis of carcinogenesis in Barrett's esophagus.Endoscopic mucosal resection of large hyperplastic polyps in 3 patients with Barrett's esophagus.Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.Barrett's esophagus and cancer risk: how research advances can impact clinical practice.Biomarkers in Barrett's Esophagus.Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus.Pathophysiology and treatment of Barrett's esophagus.Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants.Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.Barrett's esophagus and the increasing role of endoluminal therapy.Biomarkers of Barrett's esophagus.Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.Correlation of the presence and extent of loss of heterozygosity mutations with histological classifications of Barrett's esophagus.The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagusDiagnosis and grading of dysplasia in Barrett's oesophagus.Surveillance in Barrett's oesophagus: a personal viewZoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus
P2860
Q21563424-0A003269-EB38-4BD5-A1A7-A4B45C3B66F2Q24602426-191B668E-DB4E-448C-B68B-ED37317D2F53Q24685867-B65D1123-DB74-40DD-8DB8-EE4A636681E8Q24791935-A8CFE6B3-CA76-410D-99EF-93CE919B2432Q24812030-C9464806-567A-443F-8EAA-F08EEDE9C93EQ26741429-CE45AAFE-FAE8-4FCC-84D3-420BA3A76357Q26786469-C93D3426-999C-493B-B0A6-3D5FDFB16125Q26799268-72F70251-8D28-4C7B-B7AE-2BA31CE27790Q26825349-579504FD-A66C-4FC2-9649-9ED30CDD6087Q26825742-714045D6-BD7D-4568-8980-BE79FFDB821DQ26849403-5F059EF6-1998-48C1-871F-485792CA563AQ26861000-5F0A2ABD-42EA-4DDA-81BB-8B565DB7BE71Q28219148-CABAAB3C-1106-4D77-898B-23F7E0C81816Q30506094-0A702DE5-A4A4-4DB9-8BF1-2ADB094336B0Q30559268-2738D84A-028A-4145-802B-CE90C13AAE25Q30826635-FC9F573D-9173-42A3-9725-FD78ABE3312CQ33233577-7E23FDE1-A564-4477-B407-B06223851991Q33239696-B7B8C319-8AC3-44C9-BE75-BEDD1377119FQ33286792-17DFA8AE-85B0-4728-A150-56B992D2496BQ33575943-DC09DC4C-0AA3-4690-B44F-E028DBAAF640Q33600507-44C51F4A-BCE6-46D4-A9BD-12EA957873FEQ33628118-0F46C6D6-DFB9-4B46-BF9E-FEB283E17E78Q33817740-921F340D-80F3-4C07-9313-B4B2691FDDC7Q33862429-7106FEAF-7015-4CDC-AB4D-EDC688220C12Q33869267-61C18494-5AA4-4EE0-839C-58433FD486C5Q33902184-43E75184-2681-45B1-9F84-80EE11EBCB57Q33959620-513D46E2-C97C-4FEB-B0B6-5BE16BED1349Q34011000-1F6F823B-B1D3-488A-BA5A-E5C314456763Q34024948-03618C8B-824B-4ADD-B824-249F40F545E7Q34063695-AF92B7DB-F596-4FF1-A7CB-324C44BD3E41Q34310309-CDAE3F48-24F6-4B4F-B9AD-5DBF6D43300EQ34385125-64AB8B28-51E2-4A1E-97DF-9A4B48D12EFFQ34408906-84EDA2A8-AC28-4AA0-83FD-AFB260977847Q34448115-E3AA588D-D7F3-45E0-AAF8-3D5B8BE08F00Q34457732-03683F1A-8C01-4E85-B255-6AEC8F541A6DQ34523644-9A2AAC4E-EB5F-4530-925A-63467006C8D7Q34542075-B658E005-C9D2-4785-9C0D-311F2A075227Q34571587-16C95AF0-9601-42EC-BE85-ACEE4A740ACAQ34769005-44473921-D1AA-4CD8-B6B7-20C8A65C99B3Q34787887-F86B873A-2160-46C9-BDB0-D77CF103311B
P2860
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Predictors of progression to c ...... and high-risk patient subsets.
@ast
Predictors of progression to c ...... and high-risk patient subsets.
@en
type
label
Predictors of progression to c ...... and high-risk patient subsets.
@ast
Predictors of progression to c ...... and high-risk patient subsets.
@en
prefLabel
Predictors of progression to c ...... and high-risk patient subsets.
@ast
Predictors of progression to c ...... and high-risk patient subsets.
@en
P2093
P2860
P1476
Predictors of progression to c ...... and high-risk patient subsets
@en
P2093
P2860
P304
P356
10.1016/S0002-9270(00)00988-6
10.1111/J.1572-0241.2000.02196.X
P407
P577
2000-07-01T00:00:00Z